Related Experiment Video
Updated: Apr 1, 2026
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Investigational drugs for the treatment of osteoarthritis
Kang Wang1, Jianhua Xu1, David J Hunter2
1a 1 The First Affiliated Hospital of Anhui Medical University, Arthritis Research Institute, Department of Rheumatology and Immunology , Hefei, China.
Introduction:
Osteoarthritis (OA) is a common joint disease with multiple pathophysiological processes, affecting the whole joint. Current therapeutic options such as NSAIDs can provide a palliative effect on symptoms but have limited effect on disease progression. New drugs targeting OA structures may retard disease progression at an earlier stage and delay the need for joint replacement.
Areas Covered:
Some drugs have entered into clinical trials and a few, such as strontium ranelate, do have improvements in both pain and structure changes. However, most of them have failed in clinical trials largely due to increased side effects or the failure to identify the right OA phenotype for the right drug in clinical design. This review describes various investigational drugs developed for the treatment of OA covering those at stages from preclinical experiments to early phase clinical trials. They include drugs for slowing cartilage degradation, regulating cartilage metabolism, targeting subchondral bone, controlling inflammation and relieving pain.
Expert Opinion:
Treatment options for OA remain limited. However, with the emergence of sensitive tools to detect early disease progression and identification of different OA phenotypes, disease-modifying anti-OA drugs with increased benefit and reduced risks will become available for OA treatment in the near future.
Insights
New osteoarthritis (OA) drugs aim to slow disease progression, unlike current treatments. Research is exploring novel therapies targeting cartilage, bone, and inflammation for better OA management and to delay joint replacement surgery.
Area of Science:
- Orthopedics and Rheumatology
- Pharmacology and Drug Discovery
Background:
- Osteoarthritis (OA) is a prevalent joint disease with complex pathophysiology.
- Current treatments like NSAIDs offer symptomatic relief but do not halt OA progression.
- Novel therapeutics targeting OA pathology could potentially slow disease advancement and postpone joint replacement.
Purpose of the Study:
- To review investigational drugs for osteoarthritis (OA) treatment.
- To cover drugs from preclinical stages through early clinical trials.
- To highlight therapeutic strategies targeting various OA aspects.
Main Methods:
- Literature review of preclinical and clinical OA drug development.
- Analysis of drugs targeting cartilage degradation, metabolism, subchondral bone, inflammation, and pain.
- Examination of clinical trial outcomes and challenges.
Main Results:
- Several drug candidates are in development for OA.
- Strontium ranelate showed promise in pain and structural improvements.
- Many investigational drugs have faced challenges due to side effects or trial design limitations.
Conclusions:
- Limited effective treatment options currently exist for osteoarthritis.
- Advancements in early detection and OA phenotyping are crucial.
- Future development of disease-modifying drugs with improved efficacy and safety profiles is anticipated.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Ulcerative Colitis in IBD